Health Canada has granted approval for Neffy, the first needle-free epinephrine treatment for severe allergic reactions. This innovative nasal spray is designed for individuals who experience life-threatening allergies.
About Neffy
Neffy is manufactured by ALK Canada, which holds the distribution rights. The product delivers a two-milligram dose of epinephrine and is suitable for both adults and children weighing 30 kilograms (approximately 66 pounds) or more. The nasal spray is expected to be available in the Canadian market as early as this summer.
Comparison with EpiPen
The traditional treatment for severe allergic reactions has been epinephrine auto-injectors, commonly known as EpiPens. Currently, EpiPens are single-use devices that require injection into the muscle. However, Neffy’s needle-free delivery system presents a significant improvement.
- Neffy is easier to administer for those hesitant about needle use.
- The spray could potentially reduce delays in administering treatment during emergencies.
Expert Opinions
Dr. Mariam Hanna, an adjunct clinical professor of pediatrics at McMaster University, highlighted the importance of this development. She stated that Neffy removes the stress associated with using a needle. This could encourage quicker reactions in life-threatening allergy situations.
Future Perspectives
Neffy is also set to launch in the United States in summer 2024, featuring a one-milligram dosage for children weighing between 15 and 30 kilograms. However, this specific dosage has not yet been approved in Canada.
Benefits of Neffy
Key advantages of Neffy include:
- Pocket-sized design for easy portability.
- A shelf life of 30 months from the date of manufacture.
- Increased treatment options for Canadians.
- Reduction of potential supply disruptions, similar to those faced with EpiPens in 2018.
Food Allergy Canada, a non-profit organization based in Toronto, has praised the approval of Neffy, calling it a pivotal development that enhances treatment choices for Canadians facing severe allergies. This approval serves as a significant step forward in managing allergic reactions effectively.
